With the increasing number of startups using artificial intelligence in drug discovery, and pharma companies partnering with them, novel drugs and drug uses are headed to the clinic. To track them, this article summarizes the AI in drug discovery pipeline.

I do my best to keep this post up to date, but it's not easy. Not every company maintains a transparent and updated pipeline page. And several that do only disclose minimal details. So if you have information, please share it by email or in the comments.

Also, note that the number of drugs the title refers to doesn't include multiple indications for the same drug. Nor does it include "undisclosed" drugs. So it is a significant underestimate of the total pipeline. The full list below, however, shows everything, including multiple indications, and undisclosed compounds.

The AI in drug discovery pipeline

Company
Drug
Therapeutic area
Indication
Stage
Neurology
Amyotrophic lateral sclerosis and frontotemporal degeneration
Phase 3
Central nervous system
Charcot-Marie-Tooth disease type 1A adults
Phase 3
Oncology
B-cell non-Hodgkin lymphoma (monotherapy)
Phase 2
Oncology
Lymphangioleiomyomatosis
Phase 2
Oncology
B-cell non-Hodgkin lymphoma (atezolizumab combination)
Phase 2
Oncology
B-cell non-Hodgkin lymphoma (rituximab combination)
Phase 2
Oncology
Squamous cell carcinoma
Phase 2
Oncology
Pancreatic tumors
Phase 2
Neurology
Acute agitation in Alzheimer's disease or dementia
Phase 2
Neurology
Acute agitation in schizophrenia or bipolar disorder
Phase 2
Oncology
Neuroendocrine prostate cancer
Phase 2
Oncology
Pancreatic cancer
Phase 2
Infectious disease
Dengue infection
Phase 2
Infectious disease
Chikungunya infection
Phase 2
Oncology
Prostate and ovarian cancers
Phase 2
Neurology
Alzheimer's disease
Phase 2
Rare disease
Undisclosed
Phase 1
Oncology
Acute myeloid leukemia
Phase 1
Oncology
Epidermolysis bullosa
Phase 1
Oncology
Chemotherapy-induced alopecia
Phase 1
Oncology
Glioblastoma multiforma
Phase 1
Oncology
Solid tumors
Phase 1
Neurology
Mood/anxiety disorders
Phase 1
Oncology
HNSCC dose escalation
Phase 1
Oncology
Advanced or recurrent gynecological malignancies
Phase 1
Oncology
Personalized cancer immunotherapy
Phase 1
Oncology
Solid tumors
Phase 1
Oncology
Solid tumors
Phase 1
Oncology
Lung cancers
Phase 1
Rare disease
Neurofibromatosis type 2
Phase 1
Rare disease
Cerebral cavernous malformation
Phase 1
Rare disease
Undisclosed
Preclinical
Dermatology
Psoriasis
Preclinical
Dermatology
Eczema
Preclinical
Dermatology
Acne
Preclinical
Infectious disease
Superficial skin infection
Preclinical
Infectious disease
Multidrug-resistant Candida infections
Preclinical
Infectious disease
Multidrug-resistant gonorrhea
Preclinical
Infectious disease
Vaginosis
Preclinical
Oncology
Cardioprotection
Preclinical
Oncology
Hepatocellular carcinoma
Preclinical
Oncology
Undisclosed
Preclinical
Oncology
Undisclosed
Preclinical
Neurology
Opioid withdrawal
Preclinical
Neurology
Delirium
Preclinical
Oncology
Multiple tumor types
Preclinical
Neurology
Friedreich's ataxia
Preclinical
Neurology
Multiple sclerosis
Preclinical
Neurology
Multiple sclerosis
Preclinical
Central nervous system
Myalgic encephalomyelitis/chronic fatigue syndrome
Preclinical
Oncology
Thyroid cancer
Preclinical
Oncology
Gioblastoma, melanoma
Preclinical
Central nervous system
Epilepsy
Preclinical
Neurology
Leber's hereditary optic neuropathy
Preclinical
Neurology
Autism
Preclinical
Undisclosed
Undisclosed
Preclinical
Oncology
Undisclosed
Preclinical
Metabolic disease
Undisclosed
Preclinical
Oncology
Multiple oncology indications
Preclinical
Oncology
P53 basket
Preclinical
Oncology
HNSCC combination therapy
Preclinical
Oncology
HNSCC expansion
Preclinical
Oncology
Ovarian expansion
Preclinical
Metabolic disease
Wilson disease
Preclinical
Metabolic disease
Undisclosed
Preclinical
Infectious disease
3 undisclosed pathogens
Preclinical
Oncology
Personalized cancer immunotherapy
Preclinical
Infectious disease
Undisclosed
Preclinical
Oncology
Personalized cancer immunotherapy
Preclinical
Infectious disease
Cystic fibrosis, pseudomonas aeruginosa
Preclinical
Infectious disease
Skin infections, staphylococcus aureus
Preclinical
Oncology
Solid tumors
Preclinical
Rare disease
Undisclosed
Preclinical
Rare disease
Undisclosed
Preclinical
Rare disease
Undisclosed
Preclinical
Rare disease
Barth syndrome
Preclinical
Rare disease
Neuroblastoma
Preclinical
Rare disease
CDKL5 syndrome
Preclinical
Rare disease
Fragile X
Preclinical
Rare disease
Undisclosed
Preclinical
Rare disease
Pitt Hopkins
Preclinical
Oncology
Prostate and ovarian cancers
Preclinical
Oncology
Second line metastatic melanoma
Preclinical
Oncology
Second line metastatic ovarian cancer
Preclinical
Oncology
RAS pancreatic cancer
Preclinical
Central nervous system
Charcot-Marie-Tooth disease type 1A pediatric
Preclinical
Neurology
Amyotrophic lateral sclerosis
Preclinical
Oncology
Acute myelogenous leukemia
Preclinical
Rare disease
Hereditary hemorrhagic telangiectasia
Preclinical
Rare disease
Batten disease
Preclinical
Undisclosed
Undisclosed partner program
Preclinical
Rare disease
Sandhoff disease
Preclinical
Rare disease
Retinitis pigmentosa
Preclinical
Rare disease
Darier disease
Preclinical
Infectious disease
Clostridium difficile colitis
Preclinical
Gastroenterology
Ulcerative colitis
Preclinical
Rare disease
Tay-sachs disease
Preclinical
Oncology
Hematologic malignancies, primary brain tumors, neuroblastoma
Preclinical
Oncology
Metastatic breast cancer, primary brain tumors
Preclinical
Oncology
Non-small-cell lung carcinoma
Preclinical
Metabolic disease
Undisclosed metabolic condition 1
Preclinical
Oncology
Liver cancer
Preclinical
Fibrosis
Undisclosed fibrosis 2
Preclinical
Inflammation and immunology
Undisclosed inflammatory condition 1
Preclinical
Inflammation and immunology
Undisclosed immune condition 3
Preclinical
Inflammation and immunology
Undisclosed immune condition 2
Preclinical
Inflammation and immunology
Undisclosed immune condition 1
Preclinical
Fibrosis
Undisclosed fibrosis 4
Preclinical
Fibrosis
Undisclosed fibrosis 3
Preclinical
Oncology
Glioblastoma
Preclinical
Oncology
Leukemia
Discovery
Oncology
Solid tumors
Discovery
Oncology
Tumor myeloid cells
Discovery
Oncology
Protein degradation
Discovery
Oncology
Cancer and DMD
Discovery
Infectious disease
Gram - bacteria
Discovery
Cardiovascular disease
Unkown cardiovascular indication
Discovery
Oncology
Unkown cardiovascular indication
Discovery
Neurology
Neurodegenerative diseases
Discovery
Neurology
Amyotrophic lateral sclerosis
Discovery
Neurology
Amyotrophic lateral sclerosis
Discovery
Oncology
Lymphoma
Discovery
Infectious disease
Anti-viral
Discovery
Infectious disease
Tuberculosis
Discovery
Oncology
Undisclosed
Discovery
Oncology
Acute myeloid leukemia
Discovery
Metabolic disease
Non-alcoholic steatohepatitis
Discovery
Inflammation and immunology
Rheumatoid arthritis
Discovery
Infectious disease
Gram negative bacteria
Discovery
Oncology
Small cell lung cancer
Discovery
Oncology
Prostate cancer
Discovery
Oncology
Breast cancer
Discovery
Neurology
Alzheimer's disease
Discovery
Oncology
Multiple myeloma
Discovery
Neurology
Undisclosed
Discovery
Neurology
Undisclosed
Discovery
Neurology
Undisclosed
Discovery
Neurology
Undisclosed
Discovery
Neurology
Undisclosed
Discovery
Undisclosed
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Undisclosed
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Metabolic disease
Undisclosed
Discovery
Metabolic disease
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Metabolic disease
Undisclosed
Discovery
Undisclosed
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Ophthalmology
Undisclosed retinopathy
Discovery
Ophthalmology
Undisclosed retinopathy
Discovery
Metabolic disease
Wilson disease
Discovery
Metabolic disease
Wilson disease
Discovery
Metabolic disease
Wilson disease
Discovery
Ophthalmology
Undisclosed retinopathy
Discovery
Rare disease
Undisclosed
Discovery
Inflammation and immunology
Undisclosed
Discovery
Central nervous system
Undisclosed
Discovery
Neurology
Undisclosed
Discovery
Respiratory
Chronic obstructive pulmonary disease
Discovery
Oncology
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Exscientia / GT Apeiron
Oncology
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Inflammation and immunology
Undisclosed
Discovery
Inflammation and immunology
Fibrosis
Discovery
Inflammation and immunology
Undisclosed
Discovery
Oncology
Undisclosed
Discovery
Oncology
Undisclosed solid tumors
Discovery
Neurology
Multiple sclerosis
Discovery
Oncology
Triple negative breast cancer
Discovery
Oncology
Radiation sensitizer
Discovery
Oncology
Radiopaque agent
Discovery
Oncology
Chemotherapy combination
Discovery
Oncology
Radiation sensitizer
Discovery
Oncology
Advanced melanoma, KRAS-mutant pancreatic ductal adenocarcinoma
Discovery
Undisclosed
Undisclosed
Discovery
Undisclosed
Undisclosed
Discovery
Undisclosed
Reversal of T cell exhaustion
Discovery
Dermatology
Undisclosed dermatology condition 1
Discovery
Ophthalmology
Glaucoma
Discovery
Oncology
Undisclosed oncology indication 6
Discovery
Oncology
Undisclosed oncology indication 5
Discovery
Oncology
Undisclosed oncology indication 4
Discovery
Fibrosis
Endometriosis
Discovery
Neurology
Undisclosed neurological condition 1
Discovery
Rare disease
Undisclosed rare disease 1
Discovery

 

And there you have it, the AI in drug discovery pipeline, as far as I know it. Did I get anything wrong? Am I missing anything? Please let me know in the comments or by email.

And if you're craving more information on this topic, see my posts on startups using AI in drug discovery, pharma companies using AI in drug discovery, and AI in drug discovery trends and statistics.

Written By:
Simon Smith

Comments